Intellia Therapeutics Inc
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.

Postmarket

Last Trade
Delayed
$42.98
Change Since Close

Change Since Close

Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.

0.54 (1.27%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$42.44
Day's Change
2.32 (5.78%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
42.69
Day's Low
40.27
Volume
(Below Average)
Volume:
1,042,423

10-day average volume:
1,256,801
1,042,423
Historical quotes & splits

Sony Group Corp. ADR Falls Monday, Still Outperforms Market

5:36 pm ET November 28, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

The Sony Group Corp. ADR (6758.TO) shed 0.87% to $82.17 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 1.58% to 11,049.50 and Dow Jones Industrial Average falling 1.45% to 33,849.46. The ADR's fall snapped a three-day winning streak. Sony Group Corp. ADR closed $51.58 short of its 52-week high ($133.75), which the company achieved on January 5th.

The ADR demonstrated a mixed performance when compared to some of its competitors Monday, as Sharp Corp. ADR (6753.TO) fell 0.29% to $1.70, Koninklijke Philips N.V. ADR (PHIA.AE) fell 2.37% to $14.42, and Panasonic Holdings Corp. ADR (6752.TO) fell 1.08% to $9.18. Trading volume (1.1 M) eclipsed its 50-day average volume of 963,533.

Data source: Dow Jones Market Data, FactSet. Data compiled November 28, 2022.

(END) Dow Jones Newswires

November 28, 2022 17:36 ET (22:36 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.

3rd Party Research Disclosure